#USA #Clinical Trials #Veeva #Sarah Cannon #Pleasanton, California; Nashville, Tennessee

Veeva and Sarah Cannon Research Institute Unite to Advance Oncology Clinical Trials

In a significant move within the cancer research community, Veeva Systems (NYSE: VEEV) and the Sarah Cannon Research Institute (SCRI) have announced a strategic collaboration aimed at enhancing the speed and efficiency of oncology clinical trials. This partnership marks a pivotal moment for clinical research as SCRI adopts the Veeva Clinical Platform across its extensive network, which includes over 200 research sites.

The SCRI is renowned for its community-based clinical trials and has a rich history of advancing cancer therapies. By integrating the Veeva Clinical Platform into its operations, SCRI aims to unify its contract research organization (CRO) and site management organization (SMO) under a single, cohesive platform. This integration is expected to streamline data flows among clinical teams and research sites, thus promoting a more efficient research environment.

SCRI's chief information and digital officer, Yazhene Krishnaraj, expressed enthusiasm about this collaboration, stating, "We are thrilled to advance our clinical trials by integrating Veeva Clinical Platform into our digital toolkit. This strategic collaboration empowers our clinical teams to deliver groundbreaking therapies to patients with enhanced precision and speed." The implementation of this platform is designed to simplify and standardize trial processes—a crucial factor in improving how investigators and clinical teams cooperate and share essential data.

Moreover, the Veeva Clinical Platform will aid SCRI in automating vital processes, providing a smoother experience for its sites. This endeavor will not only support SCRI’s current operational needs but also pave the way for innovative approaches to oncology research in the future. According to Jim Reilly, the president of Veeva Development Cloud, this partnership is a unique opportunity to drive forward innovation in oncology research. Reilly noted, "By standardizing operations on one platform, we can support SCRI in delivering faster and more cost-effective trials."

About the Veeva Clinical Platform

The Veeva Clinical Platform is a comprehensive and interconnected system designed for clinical operations and data management across several applications. This all-inclusive platform features systems such as Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and various tools designed to enhance trial management, ensuring swift and efficient data handling throughout the study lifecycle.

By allowing real-time, connected data flow from the initiation of a study to its eventual closing, Veeva is standing at the forefront of transforming clinical research methodologies. For further insights into Veeva Clinical Platform, interested parties are encouraged to visit veeva.com/VeevaClinicalPlatform.

About the Sarah Cannon Research Institute

SCRI has established itself as a leader in oncology research, particularly in conducting community-based clinical trials aimed at developing innovative cancer therapies. With a legacy spanning over three decades, SCRI is recognized for its pivotal role in advancing drug development and improving cancer patient care. Notably, SCRI has conducted more than 850 first-in-human clinical trials and contributed to the approval of a substantial number of new cancer therapies by the FDA in recent years. With an expansive network encompassing over 1,300 physicians, SCRI has a robust presence across more than 20 states in the U.S. For additional details, visit SCRI.com.

About Veeva Systems

As a leader in cloud software solutions tailored for the life sciences sector, Veeva Systems is dedicated to fostering innovation and delivering exemplary service to its clients. With a clientele that includes some of the world's largest biopharmaceutical companies and emerging biotech firms alike, Veeva has solidified its stance as a key figure within the industry. Furthermore, as a Public Benefit Corporation, Veeva strives to balance the needs of its stakeholders including customers, employees, and investors. For more information, visit veeva.com.

This collaboration between Veeva and SCRI is set to revolutionize how clinical trials are perceived and managed in the domain of oncology research, ensuring that patients benefit from enhancements in therapeutic development at an unprecedented pace.